Hôpital Saint-Louis, AP-HP et Université de Paris VII, France.
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):860-6. doi: 10.1016/j.ijrobp.2013.03.021. Epub 2013 May 9.
To evaluate the efficacy of irradiation of internal mammary nodes (IMN) on 10-year overall survival in breast cancer patients after mastectomy.
This multicenter phase 3 study enrolled patients with positive axillary nodes (pN+) or central/medial tumors with or without pN+. Other inclusion criteria were age <75 and a Karnofsky index ≥70. All patients received postoperative irradiation of the chest wall and supraclavicular nodes and were randomly assigned to receive IMN irradiation or not. Randomization was stratified by tumor location (medial/central or lateral), axillary lymph node status, and adjuvant therapy (chemotherapy vs no chemotherapy). The prescribed dose of irradiation to the target volumes was 50 Gy or equivalent. The first 5 intercostal spaces were included in the IMN target volume, and two-thirds of the dose (31.5 Gy) was given by electrons. The primary outcome was overall survival at 10 years. Disease-free survival and toxicity were secondary outcomes.
T total of 1334 patients were analyzed after a median follow-up of 11.3 years among the survivors. No benefit of IMN irradiation on the overall survival could be demonstrated: the 10-year overall survival was 59.3% in the IMN-nonirradiated group versus 62.6% in the IMN-irradiated group (P=.8). According to stratification factors, we defined 6 subgroups (medial/central or lateral tumor, pN0 [only for medial/central] or pN+, and chemotherapy or not). In all these subgroups, IMN irradiation did not significantly improve overall survival.
In patients treated with 2-dimensional techniques, we failed to demonstrate a survival benefit for IMN irradiation. This study cannot rule out a moderate benefit, especially with more modern, conformal techniques applied to a higher risk population.
评估乳腺癌根治术后内乳淋巴结(IMN)照射对 10 年总生存的疗效。
这是一项多中心 3 期研究,纳入了腋窝淋巴结阳性(pN+)或中央/内侧肿瘤伴或不伴 pN+的患者。其他纳入标准为年龄<75 岁且 Karnofsky 指数≥70。所有患者均接受术后胸壁和锁骨上淋巴结照射,并随机分为接受或不接受 IMN 照射。随机分组按肿瘤位置(内侧/中央或外侧)、腋窝淋巴结状态和辅助治疗(化疗与无化疗)分层。目标体积的照射剂量规定为 50 Gy 或等效剂量。第一 5 个肋间隙包含在 IMN 靶区中,三分之二的剂量(31.5 Gy)由电子束给予。主要终点为 10 年总生存率。无病生存率和毒性为次要终点。
在幸存者中位随访 11.3 年后,共分析了 1334 例患者。未能证明 IMN 照射对总生存有获益:IMN 未照射组的 10 年总生存率为 59.3%,而 IMN 照射组为 62.6%(P=.8)。根据分层因素,我们定义了 6 个亚组(内侧/中央或外侧肿瘤、pN0[仅针对内侧/中央]或 pN+、以及化疗与无化疗)。在所有这些亚组中,IMN 照射均未显著改善总生存率。
在接受二维技术治疗的患者中,我们未能证明 IMN 照射有生存获益。本研究不能排除适度获益,尤其是在更高危人群中应用更现代的适形技术时。